Elizabeth Barrett - Jan 31, 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 02:40 PM
Previous filing
Jun 17, 2022
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +5K +1.62% 313K Jan 31, 2023 Direct F1
transaction URGN Ordinary Shares Options Exercise +13.3K +4.25% 327K Jan 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -5K -100% $0.00* 0 Jan 31, 2023 Ordinary Shares 5K Direct F1, F2
transaction URGN Restricted Stock Units Options Exercise $0 -13.3K -50% $0.00 13.3K Jan 31, 2023 Ordinary Shares 13.3K Direct F1, F3
transaction URGN Restricted Stock Units Award $0 +75K $0.00 75K Jan 31, 2023 Ordinary Shares 75K Direct F1, F4
transaction URGN Employee Stock Option (right to buy) Award $0 +125K $0.00 125K Jan 31, 2023 Ordinary Shares 125K $10.39 Direct F5
transaction URGN Performance Stock Units Award $0 +100K $0.00 100K Jan 31, 2023 Ordinary Shares 100K Direct F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021.
F3 The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022.
F4 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F5 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F6 Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Issuer.
F7 All shares underlying the performance stock units will vest upon achievement of a corporate milestone event.
F8 The performance stock units were approved by the Board of Directors of the Issuer on January 31, 2023. If the performance stock units are not ratified by the Issuer's shareholders at the Issuer's 2023 annual general meeting, the performance stock units will terminate.